Please login to the form below

Not currently logged in
Email:
Password:

Almirall appoints Peter Guenter as its CEO

He joins from Sanofi where he was executive vice president

Peter GuenterAlmirall has appointed Peter Guenter as its new chief executive officer, succeeding Eduardo Sanchiz who leaves to spend more time dedicated to other interests.

Guenter joins from Sanofi, where he has worked for the past 22 years, most recently as executive vice president diabetes and cardiovascular global business unit.

He said: “I am excited and eager to join Almirall as CEO. The company has a clearly defined strategy, putting the patients and customers at the centre of everything we do.

“Together with my team, I am convinced we will be able to fully unlock the value of Almirall.”

He previously held many senior positions at Sanofi, including vice president Eastern Europe and Northern Europe, vice president business management and support, general manager, Germany, and senior vice president, Europe.

Jorge Gallardo, chairman of the board, Almirall, said: “I am particularly satisfied that we have been able to attract Peter to Almirall.

“He is a truly global leader and brings a wealth of experience in US, Europe, and emerging markets. I am convinced he will bring what is needed to develop Almirall to the next level.”

Sanchiz will hand over the leadership of Almirall to Guenter during September.

30th August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics